Nagoya Firm Discovers A System To Deliver Drugs Into Brain
This article was originally published in PharmAsia News
Nagoya-based Tissue Targeting Japan Inc. has developed the T2J peptide, a synthetic molecule that is able to permeate the blood-brain barrier and deliver drugs and materials directly inside human brains. Until now, the blood-brain barrier has blocked viruses and toxins as well as drugs from entering the brain. The T2J research team discovered that the microglial cell, a certain kind of glial cell, which accounts for 90 percent of brain cells, has the ability to permeate the brain blood barrier. Modeled after the microglial cell's movement pattern inside the brain, the T2J peptide can deliver chemicals directly to the brain. Tissue Targeting Japan will strengthen joint research with pharmaceutical companies and expects to launch a new drug using the peptide in 2015. (Click here for more-Japanese language
You may also be interested in...
The European Commission has unexpectedly concluded that CBD should not be considered as drug opening up the path to regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.